US · PRPH
ProPhase Labs, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Garden City, NY 11530
- Website
- prophaselabs.com
Price · as of 2024-12-31
—
Market cap 12.38M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $23.49 | — |
| Intrinsic Value(DCF) | $1.68 | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $204.13 | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $6.53 | $890.98 | $0.29 | $0.00 | $4.29 |
| 2011 | $5.74 | $50.19 | $0.21 | $0.00 | $0.00 |
| 2012 | $9.51 | $46.19 | $0.00 | $0.40 | $0.00 |
| 2013 | $9.67 | $137.49 | $9.22 | $0.92 | $0.50 |
| 2014 | $7.12 | $398.49 | $0.00 | $0.00 | $1.48 |
| 2015 | $6.64 | $30.77 | $0.00 | $0.00 | $0.00 |
| 2016 | $10.68 | $87.43 | $0.00 | $0.00 | $0.00 |
| 2017 | $14.66 | $66.22 | $0.87 | $15.56 | $0.00 |
| 2018 | $23.72 | $55.54 | $0.36 | $0.00 | $0.00 |
| 2019 | $16.85 | $72.05 | $0.04 | $0.00 | $4.24 |
| 2020 | $63.26 | $82.42 | $0.18 | $0.00 | $0.00 |
| 2021 | $64.14 | $239.72 | $4,358.79 | $1.06 | $179.19 |
| 2022 | $66.20 | $352.17 | $22,661.36 | $0.63 | $71.00 |
| 2023 | $47.50 | $157.97 | $249.86 | $0.00 | $51.59 |
| 2024 | $4.20 | $23.49 | $0.00 | $0.00 | $204.13 |
AI valuation
Our deep-learning model estimates ProPhase Labs, Inc.'s (PRPH) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $23.49
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.68
— upside
Graham-Dodd
—
— upside
Graham Formula
$204.13
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PRPH | ProPhase Labs, Inc. | $0.30 | 12.38M | +7,780% | +464% | — | +68,378% | -1.62 | 10.90 | 11.84 | -3.22 | -0.97 | -10.50 | -2.22% | -570.59% | -788.24% | -174.58% | -79.42% | -63.85% | 3.34 | -11.53 | 0.95 | 0.65 | -0.74 | 16633.00% | -8475.00% | 2717.00% | -23.02% | -0.55 | -37.92% | 0.00% | 0.00% | 0.00% | -2.69 | -5.64 | 15.37 | -2.37 |
| AEMD | Aethlon Medical, Inc. | $4.51 | 11.72M | — | — | — | — | -0.31 | 0.80 | — | 0.06 | -0.40 | 0.80 | 0.00% | — | — | -245.88% | -1215.78% | -171.58% | 0.13 | -924.06 | 3.13 | 2.90 | 0.37 | 7654.00% | — | -2635.00% | -185.54% | -4.03 | -995.06% | 0.00% | 0.00% | 8.49% | 0.08 | 0.10 | — | -34.37 |
| ALUR | Allurion Technologies Inc… | $1.70 | 13.16M | +10,605% | -43% | — | +20,584% | -0.21 | -0.07 | 0.17 | -1.26 | — | -0.07 | 66.97% | -156.33% | -81.43% | 35.22% | 82.22% | -50.03% | -0.49 | -22.17 | 1.44 | 1.19 | -1.02 | -7987.00% | -3994.00% | -3457.00% | -785.83% | -2.24 | 70.29% | 0.00% | 0.00% | 0.00% | -0.56 | -0.65 | 0.87 | -13.22 |
| AYTU | Aytu BioPharma, Inc. | $2.17 | 13.63M | +955% | +761% | — | — | -1.04 | 0.74 | 0.21 | -1.31 | — | -0.61 | 69.04% | -11.79% | -20.43% | -58.10% | -44.62% | -11.16% | 1.21 | -2.11 | 1.26 | 0.98 | 1.72 | -2448.00% | 184.00% | 20082.00% | -36.55% | -0.03 | -29.45% | 0.00% | 0.00% | 31.33% | -0.78 | -1.18 | 0.09 | -3.20 |
| BFRI | Biofrontera Inc. | $1.09 | 11.63M | +13,983% | -66% | — | — | -0.29 | 1.14 | 0.14 | -0.28 | — | 1.15 | 50.12% | -46.14% | -47.61% | -384.98% | -281.81% | -70.99% | 1.11 | -8.17 | 1.72 | 0.93 | 0.07 | -7527.00% | 949.00% | -5851.00% | -203.55% | -0.85 | -169.15% | 0.00% | 0.00% | 99.29% | -0.24 | -0.40 | 0.11 | -7.68 |
| CODX | Co-Diagnostics, Inc. | $0.39 | 12.3M | +7,786% | +2,070% | — | +10,221% | -13.54 | 9.38 | 130.17 | -12.45 | -406.20 | 18.07 | 74.48% | -1023.75% | -961.37% | -53.65% | -140.21% | -47.25% | 0.04 | — | 4.41 | 4.08 | 0.02 | 333.00% | -4253.00% | 2754.00% | -5.87% | -3.99 | -104.61% | 0.00% | 0.00% | 0.00% | -12.03 | -16.12 | 123.12 | 29.30 |
| ERNA | Ernexa Therapeutics Inc. | $1.65 | 12.65M | +6,082% | +5% | — | — | -2.77 | 72.62 | 212.25 | -3.39 | — | -360.15 | 83.51% | -2693.13% | -7652.75% | -2264.31% | -84.37% | -163.74% | 0.40 | -2.32 | 0.80 | 0.74 | 0.03 | -6152.00% | 75588.00% | -2067.00% | -13.12% | -5.39 | -87.22% | 0.00% | 0.00% | 28.59% | -7.81 | -7.56 | 210.46 | -50.59 |
| LNAI | Lunai Bioworks Inc. | $1.17 | 20.82M | — | — | — | — | -0.19 | -1.60 | — | -2.38 | -1.04 | -1.24 | 0.00% | — | — | -321.81% | -29.94% | -207.76% | -0.48 | -25.56 | 0.04 | 0.02 | -0.55 | 1846.00% | — | -2868.00% | -23.05% | -0.27 | -12.71% | 0.00% | 0.00% | 0.00% | -2.36 | -5.57 | — | -97.67 |
| SBFM | Sunshine Biopharma, Inc. | $1.77 | 8.06M | +2,910% | +44,030,507% | — | — | -0.33 | 0.07 | 0.05 | 1.37 | — | 0.08 | 30.60% | -16.67% | -14.72% | -22.97% | -54.65% | -17.73% | 0.04 | -662.41 | 4.11 | 2.15 | 1.69 | -9792.00% | 4475.00% | 5530.00% | -885.54% | -1.98 | -146.04% | 0.00% | 0.00% | 187.20% | 1.21 | 0.48 | -0.20 | -1.74 |
| TXMD | TherapeuticsMD, Inc. | $1.19 | 13.77M | +9,622% | +5,503% | +20% | — | -4.34 | 0.37 | 5.70 | -4.07 | — | 0.44 | 100.00% | -270.30% | -123.85% | -8.16% | -15.04% | -5.63% | 0.26 | -501.05 | 1.92 | 1.67 | -0.71 | -7432.00% | 3525.00% | — | 7.30% | 0.14 | 2.34% | 0.00% | 0.00% | 15.57% | -2.55 | 16.60 | 6.90 | -34.01 |
About ProPhase Labs, Inc.
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
- CEO
- Ted William Karkus
- Employees
- 96
- Beta
- -0.68
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.68 ÷ —) − 1 = — (DCF, example).